468 related articles for article (PubMed ID: 30355587)
1. Diagnostic predictive value of Xpert Bladder Cancer Monitor in the follow-up of patients affected by non-muscle invasive bladder cancer.
D Elia C; Pycha A; Folchini DM; Mian C; Hanspeter E; Schwienbacher C; Vjaters E; Pycha A; Trenti E
J Clin Pathol; 2019 Feb; 72(2):140-144. PubMed ID: 30355587
[TBL] [Abstract][Full Text] [Related]
2. Increased accuracy of a novel mRNA-based urine test for bladder cancer surveillance.
Pichler R; Fritz J; Tulchiner G; Klinglmair G; Soleiman A; Horninger W; Klocker H; Heidegger I
BJU Int; 2018 Jan; 121(1):29-37. PubMed ID: 28941000
[TBL] [Abstract][Full Text] [Related]
3. Prospective Validation of an mRNA-based Urine Test for Surveillance of Patients with Bladder Cancer.
Valenberg FJPV; Hiar AM; Wallace E; Bridge JA; Mayne DJ; Beqaj S; Sexton WJ; Lotan Y; Weizer AZ; Jansz GK; Stenzl A; Danella JF; Shepard B; Cline KJ; Williams MB; Montgomery S; David RD; Harris R; Klein EW; Bradford TJ; Wolk FN; Westenfelder KR; Trainer AF; Richardson TA; Egerdie RB; Goldfarb B; Zadra JA; Ge S; Zhao S; Simon IM; Campbell SA; Rhees B; Bates MP; Higuchi RG; Witjes JA
Eur Urol; 2019 May; 75(5):853-860. PubMed ID: 30553612
[TBL] [Abstract][Full Text] [Related]
4. Assessment of Xpert Bladder Cancer Monitor test performance for the detection of recurrence during non-muscle invasive bladder cancer follow-up.
Cancel-Tassin G; Roupret M; Pinar U; Gaffory C; Vanie F; Ondet V; Compérat E; Cussenot O
World J Urol; 2021 Sep; 39(9):3329-3335. PubMed ID: 33770241
[TBL] [Abstract][Full Text] [Related]
5. Longitudinal follow-up and performance validation of an mRNA-based urine test (Xpert
Cowan B; Klein E; Jansz K; Westenfelder K; Bradford T; Peterson C; Scherr D; Karsh LI; Egerdie B; Witjes A; Trainer A; Harris R; Goldfarb B; Flax S; Kroeger R; Boyd B; Liao J; Patel S; Bridge J; Reuter V; Quigley N; Brown S; Zhao S; Satya M; Bates M; Simon IM; Campbell S; Lotan Y
BJU Int; 2021 Dec; 128(6):713-721. PubMed ID: 33793062
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic value of Xpert
D'Elia C; Folchini DM; Mian C; Hanspeter E; Schwienbacher C; Spedicato GA; Pycha S; Vjaters E; Degener S; Kafka M; Pycha A; Trenti E
Ther Adv Urol; 2021; 13():1756287221997183. PubMed ID: 33747133
[TBL] [Abstract][Full Text] [Related]
7. Comparison of 2 new real-time polymerase chain reaction-based urinary markers in the follow-up of patients with non-muscle-invasive bladder cancer.
Trenti E; Pycha S; Mian C; Schwienbacher C; Hanspeter E; Kafka M; Spedicato GA; Vjaters E; Degener S; Pycha A; D'Elia C
Cancer Cytopathol; 2020 May; 128(5):341-347. PubMed ID: 31977131
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic predictive value of the Bladder EpiCheck test in the follow-up of patients with non-muscle-invasive bladder cancer.
Trenti E; D'Elia C; Mian C; Schwienbacher C; Hanspeter E; Pycha A; Kafka M; Degener S; Danuser H; Roth S; Pycha A
Cancer Cytopathol; 2019 Jul; 127(7):465-469. PubMed ID: 31154670
[TBL] [Abstract][Full Text] [Related]
9. Prospective Validation of Clinical Usefulness of a Novel mRNA-based Urine Test (Xpert® Bladder Cancer Monitor) for surveillance in Non Muscle Invasive Bladder Cancer.
Elsawy AA; Awadalla A; Elsayed A; Abdullateef M; Abol-Enein H
Urol Oncol; 2021 Jan; 39(1):77.e9-77.e16. PubMed ID: 32800441
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic value of Xpert® BC Detection, Bladder Epicheck®, Urovysion® FISH and cytology in the detection of upper urinary tract urothelial carcinoma.
Pycha S; Trenti E; Mian C; Schwienbacher C; Hanspeter E; Palermo M; Pycha A; Danuser H; D'Elia C
World J Urol; 2023 May; 41(5):1323-1328. PubMed ID: 36929411
[TBL] [Abstract][Full Text] [Related]
11. Performance of the Bladder EpiCheck™ Methylation Test for Patients Under Surveillance for Non-muscle-invasive Bladder Cancer: Results of a Multicenter, Prospective, Blinded Clinical Trial.
Witjes JA; Morote J; Cornel EB; Gakis G; van Valenberg FJP; Lozano F; Sternberg IA; Willemsen E; Hegemann ML; Paitan Y; Leibovitch I
Eur Urol Oncol; 2018 Sep; 1(4):307-313. PubMed ID: 31100252
[TBL] [Abstract][Full Text] [Related]
12. Clinical performance of Xpert Bladder Cancer (BC) Monitor, a mRNA-based urine test, in active surveillance (AS) patients with recurrent non-muscle-invasive bladder cancer (NMIBC): results from the Bladder Cancer Italian Active Surveillance (BIAS) project.
Hurle R; Casale P; Saita A; Colombo P; Elefante GM; Lughezzani G; Fasulo V; Paciotti M; Domanico L; Bevilacqua G; Maffei D; Diana P; Frego N; Sandri MT; Maura F; Morenghi E; Buffi NM; Guazzoni G; Lazzeri M
World J Urol; 2020 Sep; 38(9):2215-2220. PubMed ID: 31691083
[TBL] [Abstract][Full Text] [Related]
13. The performance of the Xpert Bladder Cancer Monitor Test and voided urinary cytology in the follow-up of urinary bladder tumors.
Smrkolj T; Cegovnik Primozic U; Fabjan T; Sterpin S; Osredkar J
Radiol Oncol; 2020 Dec; 55(2):196-202. PubMed ID: 33764701
[TBL] [Abstract][Full Text] [Related]
14. Improving detection of carcinoma in situ in bladder cancer: urinary cytology vs the Xpert® BC Monitor.
Haas M; Kriegmair MC; Breyer J; Sikic D; Wezel F; Roghmann F; Brehmer M; Wirtz RM; Jarczyk J; Erben P; Bahlinger V; Goldschmidt F; Fechner G; Chen J; Paxinos E; Bates M; Zengerling F; Bolenz C; Burger M; Hartmann A; Eckstein M
BJU Int; 2024 May; ():. PubMed ID: 38717014
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of diagnostic strategies for bladder cancer using computed tomography (CT) urography, flexible cystoscopy and voided urine cytology: results for 778 patients from a hospital haematuria clinic.
Blick CG; Nazir SA; Mallett S; Turney BW; Onwu NN; Roberts IS; Crew JP; Cowan NC
BJU Int; 2012 Jul; 110(1):84-94. PubMed ID: 22122739
[TBL] [Abstract][Full Text] [Related]
16. MALBAC-based chromosomal imbalance analysis: a novel technique enabling effective non-invasive diagnosis and monitoring of bladder cancer.
Liu H; He W; Wang B; Xu K; Han J; Zheng J; Ren J; Shao L; Bo S; Lu S; Lin T; Huang J
BMC Cancer; 2018 Jun; 18(1):659. PubMed ID: 29907142
[TBL] [Abstract][Full Text] [Related]
17. Validation of an mRNA-based Urine Test for the Detection of Bladder Cancer in Patients with Haematuria.
Valenberg FJPV; Hiar AM; Wallace E; Bridge JA; Mayne DJ; Beqaj S; Sexton WJ; Lotan Y; Weizer AZ; Jansz GK; Stenzl A; Danella JF; Cline KJ; Williams MB; Montgomery S; David RD; Harris R; Klein EW; Bradford TJ; Wolk FN; Westenfelder KR; Trainer AF; Richardson TA; Egerdie RB; Goldfarb B; Zadra JA; Lu X; Simon IM; Campbell SA; Bates MP; Higuchi RG; Witjes JA
Eur Urol Oncol; 2021 Feb; 4(1):93-101. PubMed ID: 33004290
[TBL] [Abstract][Full Text] [Related]
18. Urine cell-based DNA methylation classifier for monitoring bladder cancer.
van der Heijden AG; Mengual L; Ingelmo-Torres M; Lozano JJ; van Rijt-van de Westerlo CCM; Baixauli M; Geavlete B; Moldoveanud C; Ene C; Dinney CP; Czerniak B; Schalken JA; Kiemeney LALM; Ribal MJ; Witjes JA; Alcaraz A
Clin Epigenetics; 2018; 10():71. PubMed ID: 29854012
[TBL] [Abstract][Full Text] [Related]
19. Replacing cystoscopy by urine markers in the follow-up of patients with low-risk non-muscle-invasive bladder cancer?-An International Bladder Cancer Network project.
Schmitz-Dräger C; Bonberg N; Pesch B; Todenhöfer T; Sahin S; Behrens T; Brüning T; Schmitz-Dräger BJ
Urol Oncol; 2016 Oct; 34(10):452-9. PubMed ID: 27381893
[TBL] [Abstract][Full Text] [Related]
20. Xpert® bladder cancer detection as a diagnostic tool in upper urinary tract urothelial carcinoma: preliminary results.
D'Elia C; Trenti E; Krause P; Pycha A; Mian C; Schwienbacher C; Hanspeter E; Kafka M; Palermo M; Spedicato GA; Holl S; Pycha A
Ther Adv Urol; 2022; 14():17562872221090320. PubMed ID: 35450126
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]